Eam Investors, LLC Intra Cellular Therapies, Inc. Transaction History

Eam Investors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$46.37 - $73.65 $3.11 Million - $4.95 Million	67,143 New	67,143 $4.81 Million
Q2 2023 Aug 11, 2023	BUY	$54.67 - $66.44 $1.63 Million - $1.98 Million	29,789 New	29,789 $1.89 Million
Q2 2022 Aug 12, 2022	SELL	$43.0 - $65.64 $321,683 - $491,052	-7,481 Reduced 18.55%	32,849 $1.88 Million
Q1 2022 May 13, 2022	SELL	$38.74 - $62.09 $80,346 - $128,774	-2,074 Reduced 4.89%	40,330 $2.47 Million
Q4 2021 Feb 11, 2022	BUY	$35.2 - $53.42 $1.49 Million - $2.27 Million	42,404 New	42,404 $2.22 Million
Q3 2021 Nov 12, 2021	SELL	$28.72 - $42.49 $1.38 Million - $2.05 Million	-48,220 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$29.3 - $44.5 $1.41 Million - $2.15 Million	48,220 New	48,220 $1.97 Million
Q4 2020 Feb 11, 2021	SELL	$23.34 - $32.22 $900,924 - $1.24 Million	-38,600 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$17.61 - $31.86 $679,746 - $1.23 Million	38,600 New	38,600 $990,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.